Fortunato Ciardiello
Fortunato Ciardiello
Professore di oncologia medica, seconda università di napoli
Email verificata su
Citata da
Citata da
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
A Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ...
The Lancet 389 (10066), 255-265, 2017
Epidermal growth factor-related peptides and their receptors in human malignancies
DS Salomon, R Brandt, F Ciardiello, N Normanno
Critical reviews in oncology/hematology 19 (3), 183-232, 1995
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
EGFR antagonists in cancer treatment
F Ciardiello, G Tortora
New England Journal of Medicine 358 (11), 1160-1174, 2008
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS …
E Van Cutsem, CH Köhne, I Láng, G Folprecht, MP Nowacki, S Cascinu, ...
J Clin Oncol 29 (15), 2011-2019, 2011
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
F Ciardiello, G Tortora
Clinical Cancer Research 7 (10), 2958-2970, 2001
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
F Ciardiello, R Caputo, R Bianco, V Damiano, G Pomatico, S De Placido, ...
Clinical Cancer Research 6 (5), 2053-2063, 2000
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
Chronic inflammation and oxidative stress in human carcinogenesis
A Federico, F Morgillo, C Tuccillo, F Ciardiello, C Loguercio
International journal of cancer 121 (11), 2381-2386, 2007
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
E Van Cutsem, HJ Lenz, CH Köhne, V Heinemann, S Tejpar, I Melezínek, ...
Journal of clinical oncology 33 (7), 692-700, 2015
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six …
D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ...
Annals of oncology 28 (8), 1713-1729, 2017
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
F Ciardiello, R Caputo, R Bianco, V Damiano, G Fontanini, S Cuccato, ...
Clinical cancer research 7 (5), 1459-1465, 2001
Treatment of gastric cancer
M Orditura, G Galizia, V Sforza, V Gambardella, A Fabozzi, MM Laterza, ...
World journal of gastroenterology: WJG 20 (7), 1635, 2014
Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials
S Tejpar, S Stintzing, F Ciardiello, J Tabernero, E Van Cutsem, F Beier, ...
JAMA oncology 3 (2), 194-201, 2017
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ...
Cancer research 62 (24), 7284-7290, 2002
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials
C Bokemeyer, E Van Cutsem, P Rougier, F Ciardiello, S Heeger, ...
European journal of cancer 48 (10), 1466-1475, 2012
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
W De Roock, V De Vriendt, N Normanno, F Ciardiello, S Tejpar
The lancet oncology 12 (6), 594-603, 2011
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20